Name: Relias Media
Price range: $

Study: Surgery Centers Handled COVID-19 Patients Safely

Data suggest there may be no increased risk for an asymptomatic, COVID-19-positive patient to go forward with surgery, although more research is needed before surgeons can create evidence-based guidelines.

AstraZeneca Reports 79% Efficacy for U.S. COVID-19 Vaccine Candidate

But NIH raises questions the about data.

Early Convalescent Plasma to Treat COVID-19 in Elderly Patients with Mild Symptoms

Administering convalescent plasma obtained from survivors of COVID-19 within 72 hours of onset of mild symptoms in elderly patients with the virus was associated with a significant reduction in the risk of development of severe respiratory disease.

COVID-19 Patients Can Be Managed Safely with Noninvasive Respiratory Techniques

In adult patients hospitalized with COVID-19 for one month, using a noninvasive respiratory protocol that encouraged high-flow nasal cannula, noninvasive mechanical ventilation, and self-proning did not result in any significant increase in mortality.

Healthcare Workers with COVID-19 Antibodies: Strong Protection Against Reinfection

A study of healthcare workers demonstrated the presence of antibody to SARS-CoV-2 spike protein or to nucleocapsid provides strong protection against infection for up to six months.

FDA, CDC Sign Off on Third COVID-19 Vaccine

Johnson & Johnson’s COVID-19 vaccine is the first single-shot solution to receive an agency emergency use authorization.

TJC: Support Healthcare Workers During COVID-19 Pandemic

The Joint Commission has issued the first in a series of special bulletins aimed at addressing concerns raised by healthcare workers as they respond to the continuing COVID-19 pandemic.

EDs Administer Monoclonal Antibody Therapy to High-Risk COVID-19 Patients

Clinicians can use new monoclonal antibody therapies to treat high-risk patients presenting with mild to moderate COVID-19 symptoms. However, despite the promise to depress viral loads, logistical and other challenges continue to stand in the way of larger-scale use. Still, some EDs are trying the therapeutics, with promising results.